Sven Wehrwein, a Board of Directors member at AtriCure (NASDAQ: ATRC), sold 10,000 shares after exercising non-qualified stock options, totaling ~$376,600. Post-sale, he retains 34,374 shares worth ~$1.3 million. Wehrwein’s recent transaction is the largest of three sales since August 2025, reducing his holdings by 36.78%.

AtriCure, a cardiac surgical devices company, saw Wehrwein sell 10,000 shares at $37.66 per share, above the current price of $36.12. The company reported $518.3 million in revenue with a $28.8 million net loss. Wehrwein’s remaining 34,374 shares represent 0.07% of outstanding shares.

AtriCure’s financials show revenue growth and a narrowing net loss, indicating stability. Wehrwein’s sale, although substantial, may reflect recent stock performance. With a healthy balance sheet and positive signs, shareholders may consider holding. Monitoring future net loss reduction and revenue growth is key for potential investment decisions.

Read more at Yahoo Finance: Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?